Although various international cooperative groups, including the International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN), the Children's Oncology Group (COG), and the German Society for Pediatric Oncology and Hematology (GPOH), employ slightly differing risk classification systems, they converge on assessing the following key factors to define high-risk neuroblastoma groups: the International Neuroblastoma Risk Group Staging System (INRGSS) [18] or the International Neuroblastoma Staging System (INSS) classification, age, and MYCN status [3,9,19]. The gene discussed is MYCN; the disease is neuroblastoma.